MYCOSPORIN TYPE AMINO ACID (SHINORINE) IN PRODUCTS FOR THE PREVENTION AND TREATMENT OF ACTINIC ERYTHEMA, PHOTOCARCINOGENESIS AND PHOTO AGING
Description
Free radicals are associated with a wide range of pathologies and diseases such as Alzheimer's or Parkinson's and conditions related to sun exposure such as cataracts, photoaging, inflammatory episodes and neoplasms. They are also responsible for the oxidation of fats in food, which is the most important form of deterioration after alterations produced by microorganisms. With oxidation, rancid odors and flavors appear, color and texture are altered, and nutritional value decreases as some vitamins and polyunsaturated fatty acids are lost. In addition, the products formed in oxidation can be harmful to health. An antioxidant is defined as a substance that in low concentrations compared to an oxidizable substrate, delays or prevents its oxidation. Thus, the present invention presents the potential of the amino acid type mycosporin (MAA), specifically from shinorine isolated from the red algae Gymnogongrus devoniensis, in the preparation of parapharmacy products, pharmaceutical products, nutraceutical preparations, or in functional foods, for the prevention and treatment treatment of actinic erythema, photocarcinogenesis and photoaging.
Advantages
The mycosporin-type amino acid MMA has antioxidant properties comparable to other commercial compounds with the advantage of being of natural origin.
Uses and Applications
The present invention falls within the biotechnology, pharmaceutical and food sector, and can be used as an antioxidant for the stabilization of different types of compounds, as well as food.
Keywords
       
Sectors
   
Areas
     
Patent Number
ES2301426 Expediente
Applicants
Universidad De Málaga
Inventors
Francisca De La Coba Luque, Jose Aguilera Arjona, Felix Lopez Figueroa
Filing Date
31/08/2005
Protection Level: National (Spain)
Processing Status: Spanish patent